New Global Guidelines Offer First Clear Guidance on GLP-1 Use Before, During and After Pregnancy

Doctors have a new tool to help answer a question that’s become increasingly common in exam rooms: what happens if a patient on Wegovy, Ozempic, or Mounjaro wants to get pregnant, or already is?

An international team of researchers just published the first-ever consensus guidelines on this exact topic. The guidelines appeared in Obesity Reviews, the official journal of the World Obesity Federation. Experts from 23 institutions across Europe, North America, and the Middle East worked together on the project. Dr. Shahrad Taheri of Marshall University’s Joan C. Edwards School of Medicine was the only U.S.-based researcher involved.

The timing makes sense. GLP-1 drugs have exploded in popularity for treating obesity and type 2 diabetes. But as more women of reproductive age start these medications, doctors have had surprisingly little research to lean on when patients ask about family planning.

To close that gap, the research team reviewed 34 separate studies. They looked at randomized clinical trials, observational research, safety monitoring data, and individual case reports. Their goal was simple: figure out what we actually know about these drugs and fertility, pregnancy, breastfeeding, and the postpartum period.

Here’s some good news for anyone who’s accidentally conceived while on one of these medications. The evidence didn’t show a higher risk of major birth defects when women were unknowingly exposed to GLP-1 drugs in early pregnancy. That’s reassuring, since unplanned pregnancies happen even when patients are careful about contraception.

Still, researchers want to be clear about the limits of what we know. Long-term data on how these medications during pregnancy affect mothers and children over time remains thin. So while early findings look encouraging, doctors and patients shouldn’t take that as a green light to continue treatment throughout pregnancy.

In fact, the guidelines recommend against using these drugs during pregnancy or while breastfeeding. The evidence just isn’t strong enough yet to support that use, even though the medications may offer real benefits before conception.

That’s an important distinction. Researchers found that GLP-1 medications can actually improve fertility outcomes for women dealing with polycystic ovary syndrome, now sometimes called polyendocrine metabolic ovarian syndrome, especially when obesity is part of the picture. These drugs improve insulin sensitivity, which can help restore regular ovulation in some patients. So there’s a real case for using them to help someone conceive, followed by a plan to stop once pregnancy begins.

This is where contraception counseling becomes essential. Since these medications aren’t approved for use during pregnancy, and the FDA hasn’t cleared any incretin-based drug for that purpose, doctors need to have honest conversations with patients early on. That means talking about effective birth control right from the start of treatment, not waiting until a pregnancy test comes back positive.

As GLP-1 prescriptions continue climbing nationwide, and as the monthly cost of these drugs remains a barrier for many patients, expect these guidelines to shape how professional medical groups and regulators approach the issue going forward. Pharmacovigilance systems will keep tracking real-world data too, which should help refine safety guidance as more information comes in.

Even so, the researchers were upfront about how much work remains. Nearly half of the clinically important questions around these medications and reproductive health still don’t have solid answers. That’s why they’re calling for more prospective studies and longer follow-up periods, particularly to understand how long patients should wait after stopping the drug before trying to conceive.

For now, these guidelines give clinicians a genuinely useful starting point, something that simply didn’t exist before. They won’t be the final word on the subject. But they mark real progress in an area where women and their doctors have mostly had to guess. As research continues, expect this evolving picture to sharpen, particularly around long-term safety and optimal timing for stopping treatment before pregnancy.